Hormone receptor positive HER2 negative breast cancer
Not recruitingStudy of palbociclib with hormone therapy guided by ESR1 mutation monitoring in patients with ER-positive, HER2-negative metastatic breast cancer
Study of palbociclib with hormone therapy guided by ESR1 mutation monitoring in patients with ER-positive, HER2-negative metastatic breast cancer
- Disease:Hormone receptor positive HER2 negative breast cancer
- Substances:AnastrozoleExemestane+3
France- Participants:18–64 years · 65+ years
- Substances:Anastrozole
- Sponsor:Unicancer









